title: Pharmacokinetics and toxicology of sparsomycin in beagle dogs.
abstract: Sparsomycin is a cytotoxic drug exhibiting a broad spectrum of in vitro activity against murine tumors and many tumor cell lines. It also appears to be a potent stimulator of the antitumor activity of cisplatin against L1210 leukemia in vivo. However, because of its toxicity, the antitumor activity of sparsomycin on murine tumors in vivo has been disappointing. The purpose of our study was to investigate the pharmacokinetics of this drug as well as the possible mechanisms that produce sparsomycin toxicity. Tests on beagle dogs revealed that about 60% of the drug is eliminated by metabolic clearance, while 40% is eliminated by the kidneys. After a single bolus injection of 0.1 mg/kg sparsomycin without narcosis, sparsomycin was eliminated with a t beta 1/2 of 0.6-0.7 h, the AUC being 0.32-0.38 mg.h.l-1, and the volume of distribution (Vd) 0.26 l/kg. In addition to being subject to glomerular filtration, sparsomycin is probably also actively excreted and actively reabsorbed by the renal tubuli. Sparsomycin itself may inhibit its active tubular excretion, thus resulting in a decrease in the drug's renal clearance and its accumulation in the plasma. Sparsomycin appeared to be toxic primarily in the liver, disturbing its function and the synthesis of plasma proteins. Two out of five dogs developed hemorrhagic diathesis due to hypofibrinogenemia and deficiency of other blood-coagulation factors. Sparsomycin was not toxic to the bone marrow.
authors: Department of Internal Medicine, St. Radboud Hospital, Nijmegen, The Netherlands.
authors: Z
authors: Z
authors: Zylicz
authors: D J
authors: DJ
authors: Wagener
authors: P
authors: P
authors: Fernandez del Moral
authors: H
authors: H
authors: van Rennes
authors: J M
authors: JM
authors: Wessels
authors: B
authors: B
authors: Winograd
authors: E
authors: E
authors: van der Kleijn
authors: T B
authors: TB
authors: Vree
authors: U
authors: U
authors: van Haelst
authors: L A
authors: LA
authors: van den Broek
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000493:pharmacokinetics*; D001798:Blood Proteins / Q000032:analysis; D004285:Dogs; D005123:Eye / Q000187:drug effects; D005167:Factor VII / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D013033:Sparsomycin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity
chemical_list: D000903:Antibiotics, Antineoplastic; D001798:Blood Proteins; D013033:Sparsomycin; D005167:Factor VII; D005340:Fibrinogen